AI/ML Innovations Inc. introduced its proprietary Long ECG Neural Net (L-ECG NN). The L-ECG NN provides cardiologists, researchers, pharmaceuticals and others, with a fast, accurate and comprehensive tool for the in-depth analysis and feature extraction of ECGs. The Need for Improved Utilization of ECG Data: "The ECG is the most commonly performed cardiovascular diagnostic procedure, with >100 million ECGs obtained annually in the United States." (AHA Journals).

Typical 24/48 hour-long ECGs, that are used in clinical trial, drug discovery, and specialist cases, take many days of effort for in-depth labeling, when relying on conventional, semi-automatic methods. "Even for an experienced cardiologist, accurately interpreting the ECG for a patient with concurrent arrhythmias is challenging" ? "there is an urgent unmet need for an automated or assisted multilabel ECG diagnostic framework, supported by artificial intelligence technology." The L-ECG NN Feature Set Advantage: AIML's Long ECG Neural Net displays many advantages over conventional methods of analyzing ECG data: Accurate: The L-ECG NN was trained and tested on human ECG data, providing accurate labeling with minimal (2ms) error.

In-depth: The proprietary AI analysis algorithm enables in-depth analysis and feature extraction of ECGs, allowing clinicians and researchers to quickly identify specific changes to the heartbeats of a long recording. Versatile: The advanced AI analysis algorithm provides deep analysis of ECGs from multiple sources (e.g., holters, sleep studies, clinical drug trials). Comprehensive: While rudimentary traditional methods of ECG analysis only spot the R-peak, company labels every waveform and its duration, providing comprehensive cardiac data insights.

Fast: The company is able to label all ECG features within minutes for ECGs of any size, rather than in days, as is the present case. Future potential: The L-ECG NN has the potential of using the features extracted to detect and predict cardiovascular diseases, and discovering new digital biomarkers for cardiac and chronic patients. Product Configurations: The L-ECG NN is available for hardware integration (use in 1- Lead ECG wearable monitors, 1 or 3-lead Holter monitors, and more), or for use online.

Available as a REST API, allowing developers to integrate L-ECG NN into third-party applications. A web application for easy use, without technical knowledge. While the potential user base for technology is both broad and deep, company has identified several potential market segments that represent the "path of least resistance" to market penetration.

Some of these include: Pharmaceuticals & Clinical Drug Trials, Device/ECG hardware companies (e.g. Holter monitors or patches), Researchers, Cardiology specialists, and Future Development Plans. AIML has several plans for the expansion of both the potential use and the users of the L-ECG NN technology going forward. Some of these include: Regulatory approval: FDA submission for approval as a medical device.

Online access: An incorporated User Interface (UI) for users to directly interact with the NN Store. Users will be able to directly upload their ECG data and have a full display of resulting graphs and labels to analyze and download. Diagnosis: Training of the L-ECG NN to analyze ECGs for heart abnormalities to accelerate and automate diagnoses.

Prediction: Accelerate and, eventually, automate the analysis of existing ECG databases to enable early detection and prediction of cardiovascular diseases (CVDs).